National Pension Service Buys 330,290 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

by · The Cerbat Gem

National Pension Service raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 13.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,807,643 shares of the biopharmaceutical company’s stock after acquiring an additional 330,290 shares during the period. National Pension Service owned about 0.23% of Gilead Sciences worth $235,393,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in Gilead Sciences in the second quarter valued at $25,328,000. Legal & General Group Plc boosted its stake in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC acquired a new position in Gilead Sciences in the third quarter worth $830,000. GSA Capital Partners LLP acquired a new position in Gilead Sciences in the first quarter worth $462,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Gilead Sciences by 13.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after purchasing an additional 33,162 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on GILD. Raymond James raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday, July 8th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Finally, Wells Fargo & Company raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Ten equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

View Our Latest Report on Gilead Sciences

Gilead Sciences Trading Up 0.6 %

NASDAQ GILD opened at $90.08 on Monday. The stock has a 50-day simple moving average of $83.79 and a 200 day simple moving average of $74.21. The company has a market capitalization of $112.15 billion, a PE ratio of 109.16, a P/E/G ratio of 3.09 and a beta of 0.17. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $90.30.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Research analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).